PURPOSE: Genomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched targeted therapy (MTT) when available. PATIENTS AND METHODS: Patients with advanced cancer who underwent tumor genomic analyses were treated with MTT when available. RESULTS: Overall, 1,179 (82.1%) of 1,436 patients had one or more alterations (median age, 59.7 years; men, 41.2%); 637 had one or more actionable aberrations and were treated with MTT (n = 390) or non-MTT (n = 247). Patients who were treated with MTT had higher rates of complete and partial response (11% v 5%; P = .0099), longer failure-free survival (FFS; 3.4 v 2.9 months; P = .0015), and longer overall survival (OS; 8.4 v 7.3 months; P = .041) than did unmatched patients. Two-month landmark analyses showed that, for MTT patients, FFS for responders versus nonresponders was 7.6 versus 4.3 months (P < .001) and OS was 23.4 versus 8.5 months (P < .001), whereas for non-MTT patients (responders v nonresponders), FFS was 6.6 versus 4.1 months (P = .001) and OS was 15.2 versus 7.5 months (P = .43). Patients with phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase pathway alterations matched to PI3K/Akt/mammalian target of rapamycin axis inhibitors alone demonstrated outcomes comparable to unmatched patients. CONCLUSION: Our results support the use of genomic matching. Subset analyses indicate that matching patients who harbor a PI3K and mitogen-activated protein kinase pathway alteration to only a PI3K pathway inhibitor does not improve outcome. We have initiated IMPACT2, a randomized trial to compare treatment with and without genomic selection.
PURPOSE: Genomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched targeted therapy (MTT) when available. PATIENTS AND METHODS: Patients with advanced cancer who underwent tumor genomic analyses were treated with MTT when available. RESULTS: Overall, 1,179 (82.1%) of 1,436 patients had one or more alterations (median age, 59.7 years; men, 41.2%); 637 had one or more actionable aberrations and were treated with MTT (n = 390) or non-MTT (n = 247). Patients who were treated with MTT had higher rates of complete and partial response (11% v 5%; P = .0099), longer failure-free survival (FFS; 3.4 v 2.9 months; P = .0015), and longer overall survival (OS; 8.4 v 7.3 months; P = .041) than did unmatched patients. Two-month landmark analyses showed that, for MTTpatients, FFS for responders versus nonresponders was 7.6 versus 4.3 months (P < .001) and OS was 23.4 versus 8.5 months (P < .001), whereas for non-MTTpatients (responders v nonresponders), FFS was 6.6 versus 4.1 months (P = .001) and OS was 15.2 versus 7.5 months (P = .43). Patients with phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase pathway alterations matched to PI3K/Akt/mammalian target of rapamycin axis inhibitors alone demonstrated outcomes comparable to unmatched patients. CONCLUSION: Our results support the use of genomic matching. Subset analyses indicate that matching patients who harbor a PI3K and mitogen-activated protein kinase pathway alteration to only a PI3K pathway inhibitor does not improve outcome. We have initiated IMPACT2, a randomized trial to compare treatment with and without genomic selection.
Authors: Daniel D Von Hoff; Joseph J Stephenson; Peter Rosen; David M Loesch; Mitesh J Borad; Stephen Anthony; Gayle Jameson; Susan Brown; Nina Cantafio; Donald A Richards; Tom R Fitch; Ernesto Wasserman; Cristian Fernandez; Sylvan Green; William Sutherland; Michael Bittner; Arlet Alarcon; David Mallery; Robert Penny Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Filip Janku; David S Hong; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Gerald S Falchook; Apostolia M Tsimberidou; Vanda M Stepanek; Stacy L Moulder; J Jack Lee; Rajyalakshmi Luthra; Ralph G Zinner; Russell R Broaddus; Jennifer J Wheler; Razelle Kurzrock Journal: Cell Rep Date: 2014-01-16 Impact factor: 9.423
Authors: Maria Schwaederle; Gregory A Daniels; David E Piccioni; Paul T Fanta; Richard B Schwab; Kelly A Shimabukuro; Barbara A Parker; Razelle Kurzrock Journal: Mol Cancer Ther Date: 2015-04-07 Impact factor: 6.261
Authors: Jennifer J Wheler; Filip Janku; Aung Naing; Yali Li; Bettzy Stephen; Ralph Zinner; Vivek Subbiah; Siqing Fu; Daniel Karp; Gerald S Falchook; Apostolia M Tsimberidou; Sarina Piha-Paul; Roosevelt Anderson; Danxia Ke; Vincent Miller; Roman Yelensky; J Jack Lee; David Hong; Razelle Kurzrock Journal: Mol Cancer Ther Date: 2016-07-27 Impact factor: 6.261
Authors: Apostolia-Maria Tsimberidou; Nancy G Iskander; David S Hong; Jennifer J Wheler; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Aung Naing; Filip Janku; Rajyalakshmi Luthra; Yang Ye; Sijin Wen; Donald Berry; Razelle Kurzrock Journal: Clin Cancer Res Date: 2012-09-10 Impact factor: 12.531
Authors: Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong Journal: Cancer Discov Date: 2011-06-01 Impact factor: 39.397
Authors: Rabih Said; Yang Ye; David S Hong; Filip Janku; Siqing Fu; Aung Naing; Jennifer J Wheler; Razelle Kurzrock; Christoforos Thomas; Gary A Palmer; Kenneth R Hess; Kenneth Aldape; Apostolia M Tsimberidou Journal: Oncotarget Date: 2014-06-15
Authors: Michael J Pishvaian; Edik M Blais; Jonathan R Brody; Emily Lyons; Patricia DeArbeloa; Andrew Hendifar; Sam Mikhail; Vincent Chung; Vaibhav Sahai; Davendra P S Sohal; Sara Bellakbira; Dzung Thach; Lola Rahib; Subha Madhavan; Lynn M Matrisian; Emanuel F Petricoin Journal: Lancet Oncol Date: 2020-03-02 Impact factor: 41.316
Authors: Jordi Rodon; Jean-Charles Soria; Raanan Berger; Wilson H Miller; Eitan Rubin; Aleksandra Kugel; Apostolia Tsimberidou; Pierre Saintigny; Aliza Ackerstein; Irene Braña; Yohann Loriot; Mohammad Afshar; Vincent Miller; Fanny Wunder; Catherine Bresson; Jean-François Martini; Jacques Raynaud; John Mendelsohn; Gerald Batist; Amir Onn; Josep Tabernero; Richard L Schilsky; Vladimir Lazar; J Jack Lee; Razelle Kurzrock Journal: Nat Med Date: 2019-04-22 Impact factor: 53.440